(a) an extracellular domain of a human Notch1 receptor protein, followed by(b) an Fc portion of an antibody,wherein the extracellular domain of the human Notch1 receptor protein (i) commences with the amino acid present at the N-terminus of EGF-like repeat 10 and(ii) extends to and includes the C-terminal amino acid of EGF-like repeat 18 or 20.;Also provided is a composition comprising the any of the fusion proteins of this invention and a pharmaceutically acceptable carrier, a method of treating a subject suffering from age-related macular degeneration (AMD), diabetic retinopathy, or cancer which comprises administering to the subject any of the compositions of this invention in an amount effective to treat the subject's cancer."/> Human Notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and DLL-notch signaling
首页> 外国专利> Human Notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and DLL-notch signaling

Human Notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and DLL-notch signaling

机译:基于人Notch1的融合蛋白作为锯齿状信号传导信号和DLL-Notch信号传导的诱饵抑制剂

摘要

This invention provides a fusion protein, the sequence of which, commencing at the N-terminus of the fusion protein, is identical to the sequence of amino acids in:(a) an extracellular domain of a human Notch1 receptor protein, followed by(b) an Fc portion of an antibody,wherein the extracellular domain of the human Notch1 receptor protein (i) commences with the amino acid present at the N-terminus of EGF-like repeat 10 and(ii) extends to and includes the C-terminal amino acid of EGF-like repeat 18 or 20.;Also provided is a composition comprising the any of the fusion proteins of this invention and a pharmaceutically acceptable carrier, a method of treating a subject suffering from age-related macular degeneration (AMD), diabetic retinopathy, or cancer which comprises administering to the subject any of the compositions of this invention in an amount effective to treat the subject's cancer.
机译:本发明提供了一种融合蛋白,其序列在融合蛋白的N-末端开始,与氨基酸序列相同: (a)人Notch1受体蛋白的细胞外结构域,其次是 (b)抗体的Fc部分, 其中人Notch1受体蛋白的细胞外结构域 (i)开始与eGF的N-末端的氨基酸存在于类似EGF的重复10和< / listitem> (ii)延伸至并且包括EGF样重复18或20的C末端氨基酸。 ;还提供了一种组合物,其包含本发明的任何融合蛋白和药学上可接受的载体,一种治疗患有年龄相关性黄斑变性的受试者的方法( AMD),糖尿病视网膜病变或癌症,其包括向受试者施用本发明的任何组合物,其量有效治疗受试者的癌症。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号